133 related articles for article (PubMed ID: 20071170)
1. Identification of potent and selective VEGFR receptor tyrosine kinase inhibitors having new amide isostere headgroups.
Gaudette F; Raeppel S; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Macleod AR; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2010 Feb; 20(3):848-52. PubMed ID: 20071170
[TBL] [Abstract][Full Text] [Related]
2. N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Raeppel S; Claridge S; Saavedra O; Gaudette F; Zhan L; Mannion M; Zhou N; Raeppel F; Granger MC; Isakovic L; Déziel R; Nguyen H; Beaulieu N; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman J; Vaisburg A
Bioorg Med Chem Lett; 2009 Mar; 19(5):1323-8. PubMed ID: 19211249
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of benzamides and benzamidines as selective inhibitors of VEGFR tyrosine kinases.
Nakamura H; Sasaki Y; Uno M; Yoshikawa T; Asano T; Ban HS; Fukazawa H; Shibuya M; Uehara Y
Bioorg Med Chem Lett; 2006 Oct; 16(19):5127-31. PubMed ID: 16893647
[TBL] [Abstract][Full Text] [Related]
4. Arylphthalazines: identification of a new phthalazine chemotype as inhibitors of VEGFR kinase.
Piatnitski EL; Duncton MA; Kiselyov AS; Katoch-Rouse R; Sherman D; Milligan DL; Balagtas C; Wong WC; Kawakami J; Doody JF
Bioorg Med Chem Lett; 2005 Nov; 15(21):4696-8. PubMed ID: 16143524
[TBL] [Abstract][Full Text] [Related]
5. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Hess-Stumpp H; Haberey M; Thierauch KH
Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
[TBL] [Abstract][Full Text] [Related]
6. 8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors.
Hudkins RL; Zulli AL; Underiner TL; Angeles TS; Aimone LD; Meyer SL; Pauletti D; Chang H; Fedorov EV; Almo SC; Fedorov AA; Ruggeri BA
Bioorg Med Chem Lett; 2010 Jun; 20(11):3356-60. PubMed ID: 20430619
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a novel and potent series of dianilinopyrimidineurea and urea isostere inhibitors of VEGFR2 tyrosine kinase.
Sammond DM; Nailor KE; Veal JM; Nolte RT; Wang L; Knick VB; Rudolph SK; Truesdale AT; Nartey EN; Stafford JA; Kumar R; Cheung M
Bioorg Med Chem Lett; 2005 Aug; 15(15):3519-23. PubMed ID: 15990302
[TBL] [Abstract][Full Text] [Related]
8. A highly selective, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor has potent activity in vitro and in vivo.
LaMontagne KR; Butler J; Borowski VB; Fuentes-Pesquera AR; Blevitt JM; Huang S; Li R; Connolly PJ; Greenberger LM
Angiogenesis; 2009; 12(3):287-96. PubMed ID: 19544081
[TBL] [Abstract][Full Text] [Related]
9. Quinazoline-urea, new protein kinase inhibitors in treatment of prostate cancer.
Garofalo A; Goossens L; Lemoine A; Farce A; Arlot Y; Depreux P
J Enzyme Inhib Med Chem; 2010 Apr; 25(2):158-71. PubMed ID: 20222760
[TBL] [Abstract][Full Text] [Related]
10. 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski E
Bioorg Med Chem Lett; 2006 Mar; 16(6):1726-30. PubMed ID: 16364640
[TBL] [Abstract][Full Text] [Related]
11. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
12. Application of genomics for identification of systemic toxicity triggers associated with VEGF-R inhibitors.
Hamadeh HK; Todd M; Healy L; Meyer JT; Kwok AM; Higgins M; Afshari CA
Chem Res Toxicol; 2010 Jun; 23(6):1025-33. PubMed ID: 20521778
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
14. 4-(Azolylphenyl)-phthalazin-1-amines: Novel inhibitors of VEGF receptors I and II.
Kiselyov AS; Semenov VV; Milligan D
Chem Biol Drug Des; 2006 Dec; 68(6):308-13. PubMed ID: 17177892
[TBL] [Abstract][Full Text] [Related]
15. Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase inhibitors by in silico high-throughput screening.
Usui T; Ban HS; Kawada J; Hirokawa T; Nakamura H
Bioorg Med Chem Lett; 2008 Jan; 18(1):285-8. PubMed ID: 17983745
[TBL] [Abstract][Full Text] [Related]
16. Discovery of potent vascular endothelial growth factor receptor-2 inhibitors.
Papakyriakou A; Katsarou ME; Belimezi M; Karpusas M; Vourloumis D
ChemMedChem; 2010 Jan; 5(1):118-29. PubMed ID: 19921722
[TBL] [Abstract][Full Text] [Related]
17. Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.
Wissner A; Fraser HL; Ingalls CL; Dushin RG; Floyd MB; Cheung K; Nittoli T; Ravi MR; Tan X; Loganzo F
Bioorg Med Chem; 2007 Jun; 15(11):3635-48. PubMed ID: 17416531
[TBL] [Abstract][Full Text] [Related]
18. N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.
Kiselyov AS; Piatnitski E; Semenova M; Semenov VV
Bioorg Med Chem Lett; 2006 Feb; 16(3):602-6. PubMed ID: 16275072
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
Bauer D; Whittington DA; Coxon A; Bready J; Harriman SP; Patel VF; Polverino A; Harmange JC
Bioorg Med Chem Lett; 2008 Sep; 18(17):4844-8. PubMed ID: 18682324
[TBL] [Abstract][Full Text] [Related]
20. Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.
Kiselyov AS; Semenova M; Semenov VV; Piatnitski E; Ouyang S
Bioorg Med Chem Lett; 2006 Mar; 16(5):1440-4. PubMed ID: 16321531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
